Celcuity Inc. develops targeted oncology therapies as a clinical-stage biotechnology company, with news centered on gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor for solid tumors. Company updates frequently cover Phase 3 VIKTORIA-1 data in HR+/HER2- advanced breast cancer, including PIK3CA wild-type and mutant cohorts and combination regimens with fulvestrant and palbociclib.
Recurring announcements also address FDA regulatory submissions and review status for gedatolisib, publications and medical-meeting presentations, quarterly financial results, corporate updates, investor conference participation, and board governance changes.
Celcuity (Nasdaq: CELC) announced FDA acceptance of its supplemental application to expand REVTORPYK use to PIK3CA-mutant advanced breast cancer. The FDA set a June 25, 2027 target decision date. The proposed indication covers HR-positive, HER2-negative locally advanced or metastatic breast cancer with a PIK3CA mutation after progression on or after at least one line of endocrine therapy in the metastatic setting.
The application draws on the PIK3CA-mutant cohort of the Phase 3 VIKTORIA-1 trial. REVTORPYK, or gedatolisib, received FDA approval on July 14, 2026, with fulvestrant, with or without palbociclib, for the corresponding population without a detected PIK3CA mutation. Celcuity said approval of the expansion would make REVTORPYK available as second-line therapy regardless of tumor PIK3CA status. The expanded indication remains under review.
Celcuity (Nasdaq: CELC) reported a third-quarter net loss of $73.3 million as it began commercializing its first approved drug. Loss per share was $1.33 versus $0.92 a year earlier. REVTORPYK became commercially available September 30, 2026, for previously treated HR-positive, HER2-negative advanced breast cancer without a detected PIK3CA mutation, in combination with fulvestrant, with or without palbociclib. No product revenue was recognized in the quarter.
Health plans covering 91% of U.S. commercial and Medicare lives cover REVTORPYK; 78% of the top 36 strategic accounts have ordered it. Celcuity submitted an application for an additional indication involving PIK3CA-mutant breast cancer. Quarterly operating cash use rose to $66.2 million from $44.8 million, alongside a separate $50.0 million Pfizer payment. Cash and short-term investments totaled $642.7 million; Celcuity expects funding through 2029.
Celcuity (CELC) announced that CEO and co-founder Brian Sullivan will participate in investor conferences on November 10, 11 and 18, 2026. He will hold fireside chats at Guggenheim’s Healthcare Innovation Conference, Stifel’s Healthcare Conference and Jefferies Global Healthcare Conference in London, and be available for one-on-one investor meetings. Live webcasts and subsequent replays will be accessible through the company’s investor website.
Celcuity (CELC) will release its third-quarter 2026 financial results after the market closes on November 5, 2026.
Management will host a webcast and teleconference that day at 4:30 p.m. Eastern Standard Time to discuss the results and provide a corporate update. A webcast replay will be available on the company website after the live event.
Celcuity (Nasdaq: CELC) presented updated Phase 3 VIKTORIA-1 results for gedatolisib in patients with PIK3CA-mutant advanced breast cancer at ESMO 2026.
The triplet combines gedatolisib, fulvestrant and palbociclib; the doublet omits palbociclib. Without liver metastases, median progression-free survival, or time without cancer worsening or death, was 21.5 months with the triplet and 11.5 months with the doublet, versus 9.1 months with alpelisib plus fulvestrant. With liver metastases, results were 9.1, 11.1 and 4.6 months, respectively.
In evaluable mutant-cohort patients, response rates were 59%, 43% and 33%; median response durations were 19.4, 27.8 and 7.5 months, respectively. Adverse-event discontinuation rates were 5% and 4% for gedatolisib versus 19% for alpelisib. The doublet's no-liver-metastases comparison had a p-value of 0.1627, qualifying the broader efficacy findings.
Celcuity (CELC) presented updated Phase 1b/2 results for gedatolisib plus darolutamide in men with metastatic castration-resistant prostate cancer at ESMO 2026.
The study enrolled 45 patients. At the August 14, 2026 cutoff, median radiographic progression-free survival, the time without imaging-detected progression or death, was 15.7 months in patients previously treated with abiraterone and 9.1 months after enzalutamide. Six-month rates were 82.2% and 62.5%, respectively. Rates of prostate-specific antigen decreases of at least 50% were 36%, 47% and 67% at the respective 120-, 180- and 240-mg gedatolisib doses. Grade 3 treatment-related adverse events occurred in 20% of patients; none were Grade 4/5 or led to discontinuation or death. Celcuity expects Phase 2 to begin in the first half of 2027, after Phase 1b completion.
Celcuity (CELC) will feature four gedatolisib presentations at the ESMO Congress, held October 23–27, 2026, in Madrid, Spain. The program includes a late-breaking rapid oral presentation on October 24 covering updated Phase 3 VIKTORIA-1 results, including additional subgroup analyses from the PIK3CA mutant-type breast cancer cohort.
Three posters cover a comparative analysis of the VIKTORIA-1 PIK3CA wild-type cohort against other breast cancer regimens, gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer, and the Phase 3 VIKTORIA-2 first-line breast cancer study. Abstracts will be published on the ESMO website on October 19, 2026.
Celcuity (CELC) appointed David W. Gryska to its Board of Directors as the biotechnology company transitions into a commercial-stage business. Gryska brings over 35 years of financial and strategic leadership experience in life sciences, including former chief financial officer roles at Incyte and Celgene.
The appointment follows Celcuity’s first FDA approval for REVTORPYK. The company expects Gryska to support the product launch and continued clinical development. He has served on the boards of eight public biotechnology companies over the past 25 years and currently serves on Definium Therapeutics’ board.
Celcuity (CELC) has made REVTORPYK (gedatolisib) commercially available in the United States for eligible patients with advanced breast cancer. The FDA approved it on July 14, 2026, with fulvestrant, with or without palbociclib. Eligibility covers adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer without a detected PIK3CA mutation, following progression on or after at least one endocrine therapy in the metastatic setting.
In the Phase 3 VIKTORIA-1 cohort without PIK3CA mutations, the three-drug and two-drug combinations reduced the risk of progression or death by 76% and 67%, respectively, versus fulvestrant. Celcuity submitted an additional FDA application in August for patients with PIK3CA-mutated advanced breast cancer; that use remains conditional on approval. The company also launched REVTORPYK Support Services for insurance coverage, financial assistance and treatment enrollment.
Celcuity (Nasdaq: CELC) announced that CEO and co-founder Brian Sullivan will participate in two upcoming investor conferences. He will join a fireside chat at the Wells Fargo 21st Annual Healthcare Conference/b) at 10:15 a.m. EDT on Tuesday, September 8, 2026, and a fireside chat at at 8:00 a.m. EDT on Wednesday, September 9, 2026. Live webcasts for both events will be accessible via conference weblinks and through the Investors section of Celcuity's website, with replays available shortly after the live events.